Post-earnings recap
Reported
Wed, Aug 1, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
United Therapeutics reported better-than-expected earnings per share, which indicates strong operational performance. However, the stock fell by over 5% on the day, likely due to the absence of revenue figures and forward guidance. Investors may be cautious as they await more detailed information on future performance and product developments.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.36 | N/A | +24.39% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a positive outlook regarding their product pipeline. However, they did not provide specific guidance for future quarters.
Management highlighted strong performance in their key product areas.
They expressed confidence in their ongoing research and development efforts.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—